ARK Genomic Profile

AG
ARK Genomic is trading at 55.72 as of the 13th of July 2020, which is 3.22% increase since the beginning of the trading day. The etf's lowest day price was 55.61. ARK Genomic has a very small chance of experiencing financial distress in the next few years and had a very solid performance during the last 30 days. Equity ratings for ARK Genomic Revolution are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 14th of April 2020 and ending today, the 13th of July 2020. Click here to learn more.
Analyze Filter   Check how we calculate scores

   Performance
18 100 

ARK Genomic Profile

The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . ARK Genomic is traded on BATS Exchange in the United States. more on ARK Genomic
Legal NameARK Genomic Revolution
Thematic Classification
Currently Active Investing Idea
  Healthcare Funds
View All
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of ARK Genomic available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
IssuerARK
DescriptionARK Genomic Revolution Multi-Sector ETF
Inception Date2014-10-30
BenchmarkNot Applicable
Entity TypeRegulated Investment Company
Asset Under Management1.38 Billion
Average Trading Valume616,301.6
Asset TypeEquity
CategoryStrategy
FocusTheme
Market ConcentrationBlended Development
RegionGlobal
AdministratorThe Bank of New York Mellon Corporation
AdvisorARK Investment Management LLC
CustodianThe Bank of New York Mellon Corporation
DistributorForeside Fund Services, LLC
Portfolio ManagerCatherine D. Wood
Transfer AgentThe Bank of New York Mellon Corporation
Fiscal Year End31-Dec
ExchangeNYSE Arca, Inc.
Number of Constituents41.0
Market MakerJane Street
Total Expense0.75
Management Fee0.75
Nav Price54.08
Two Hundred Day Average38.18
Ytd38.25%
Average Daily Volume In Three Month541.86k
Fifty Two Week Low24.0
As Of Date31st of May 2020
Average Daily Volume Last 10 Day577.85k
Fifty Two Week High54.75
One Month13.89%
Fifty Day Average47.97
Three Month34.75%
ARK Genomic Revolution [ARKG] is traded in USA and was established 2014-10-30. The fund is listed under Health category and is part of ARK ETF Trust family. The entity is thematically classified as Healthcare Funds. ARK Genomic Revolution presently have 1.04 B in assets under management (AUM). , while the total return for the last 3 years was 36.11%.
Check ARK Genomic Probability Of Bankruptcy

Geographic Allocation (%)

Sector Allocation (%)

Top ARK Genomic Revolution Constituents

ARK Genomic Target Price Odds Analysis

Odds Down 55.72HorizonTargetOdds Up 55.72
96.07%30 days
 55.72 
3.90%
Based on a normal probability distribution, the odds of ARK Genomic to move above the current price in 30 days from now is under 4 (This ARK Genomic Revolution probability density function shows the probability of ARK Genomic Etf to fall within a particular range of prices over 30 days) .

ARK Genomic Top Holders

ARK Genomic Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Advocacy Wealth Management Services LlcFund Units45 K2.3 M
View ARK Genomic Diagnostics

ARK Genomic Revolution Risk Profiles

ARK Genomic Revolution Technical Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Cosh Values Of ARK Genomic Price Series is a hyperbolic price transformation function. View also all equity analysis or get more info about cosh values of price series math transform indicator.

ARK Genomic Against Markets

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

ARK Genomic Distributions to stockholders

A dividend is the distribution of a portion of ARK Genomic earnings, decided and managed by the ARK Genomics board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. ARK Genomic dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment.
27th of December 2019
Please continue to Trending Equities. Please also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page